Guard therapeutics

See the webcast. Guard therapeutics Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue, guard therapeutics.

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. Financial Times Close.

Guard therapeutics

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC The company's Chief Medical Officer, Dr. CEO Tobias Agervald then presented new advancements in the company's preclinical development platform, the so-called GTX platform, aimed at developing new peptides short protein fragments based on the endogenous protein alphamicroglobulin. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. Additional concept validation studies have also been conducted with up to 28 days of treatment in two models of chronic kidney disease, including diabetes-induced kidney disease and focal segmental glomerulosclerosis FSGS. With these results, the company sees promising opportunities to strengthen and expand its position in several new potential therapy areas, including chronic kidney disease.

Financial calender Financial reports Share information Corporate governance General meetings. TradeDoubler AB. Maximum Entertainment AB.

.

The global study is planned to be conducted in Europe and North America under the guidance of Prof. The randomised, double-blind, placebo-controlled global phase 2 study of ROSgard is expected to include around patients who are undergoing open heart surgery and are thus at risk of developing acute kidney injury. The study is planned to start in the first quarter of and German study centres are expected to recruit a significant proportion of the total number of patients. The company awaits ethical approval of the study as a last step in the German clinical trial application procedure before the study can start. Among other properties, the investigational drug ROSgard has the ability to counteract severe oxidative stress, which is a common denominator for many types of acute kidney injury. In the initial clinical development phase Guard Therapeutics has chosen to give priority to treatment in connection with open heart surgery using a heart-lung machine. In case of a positive outcome, the global phase 2 study is expected to pave the way for a subsequent registrational study. There is also an option to expand the continued clinical programme to other segments, such as patients undergoing kidney transplants.

Guard therapeutics

In line with previous communication patient recruitment was prematurely stopped, and as expected the primary short-term endpoint, incidence of acute kidney injury AKI within 72 hours after surgery, was not reached. Importantly though, pre-defined secondary endpoints demonstrated the intended long-term benefit of RMC with improved kidney function compared to placebo. These results clearly support advancement in the clinical development program and highlight the potential of RMC as a novel short-term treatment for kidney protection. With these results we are back on track, strengthened in our confidence to establish a new and unique treatment for the prevention of kidney injuries in heart surgery and proceed with the clinical development of RMC as planned. The consistency between improved kidney function and MAKE reduction in the stable phase after surgery is compelling because these outcome measures offer distinct perspectives on assessing the kidney-protective treatment effect. As the lead investigator of the AKITA trial, I am eager to see the compound's further development progress and ultimate contribution to improving patient outcomes," said Prof. Alexander Zarbock. The AKITA study is a randomized, double-blind, placebo-controlled Phase 2 study of RMC in patients undergoing open-heart surgery and at increased risk to develop kidney injuries. A total of patients were randomized and dosed in the study 89 in the RMC group, 88 in the placebo group.

Guardian childcare & education charlotte street

Acute kidney injury is a large market. Maximum Entertainment AB. Guard Therapeutics Intrntnl AB publ. Financial calender Financial reports Share information Corporate governance General meetings. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. RMC, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue. Any information that you receive via FT. With these results, the company sees promising opportunities to strengthen and expand its position in several new potential therapy areas, including chronic kidney disease. Published: CET. Fable Media Group AB. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Price SEK The company's Chief Medical Officer, Dr. Arribatec Group ASA. HomeMaid AB publ.

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented.

The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. Food and Drug Administration FDA granted RMC ROSgard Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Latest Press Releases. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. Read more. Show more Personal Finance link Personal Finance. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Guard Therapeutics Intrntnl AB publ. This news release was distributed by Company News System, www. Published: CET. Guard Therapeutics announced that the U. Acute kidney injury is a large market. See the webcast. Speqta AB publ. Add to Your Watchlists New watchlist.